# A Randomized Controlled Study on the Treatment of Cirrhosis Combined With Hypersplenism

> **NCT05055713** · NA · UNKNOWN · sponsor: **Qilu Hospital of Shandong University** · enrollment: 368 (estimated)

## Conditions studied

- Liver Cirrhosis
- Esophageal and Gastric Varices
- Hypersplenism

## Interventions

- **PROCEDURE:** Endoscopic therapy+ beta blockers
- **PROCEDURE:** Endoscopic therapy+ PSE+beta blockers
- **PROCEDURE:** Endoscopic therapy
- **PROCEDURE:** Endoscopic therapy+ PSE
- **PROCEDURE:** Endoscopic therapy+Somatostatin
- **PROCEDURE:** Endoscopic therapy+PSE+Somatostatin

## Key facts

- **NCT ID:** NCT05055713
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-25
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 368 (ESTIMATED)
- **Last updated:** 2022-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05055713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05055713, "A Randomized Controlled Study on the Treatment of Cirrhosis Combined With Hypersplenism". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05055713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*